|1.||Gonzalez, Rene: 3 articles (01/2011 - 12/2006)|
|2.||Bedikian, Agop Y: 2 articles (06/2010 - 06/2008)|
|3.||Agarwala, Sanjiv S: 1 article (03/2015)|
|4.||Chowdhery, Rozina: 1 article (01/2011)|
|5.||Atkins, Michael B: 1 article (06/2010)|
|6.||Richards, Jon: 1 article (06/2010)|
|7.||Kharkevitch, Dmitri: 1 article (06/2010)|
|8.||Whitman, Eric: 1 article (06/2010)|
|9.||Del Vecchio, Michele: 1 article (06/2008)|
|10.||Nemunaitis, John: 1 article (12/2006)|
|1.||Melanoma (Melanoma, Malignant)
06/01/2010 - "A phase 2 dose-escalation study (VCL-1005-208) was conducted to evaluate the safety and efficacy of Allovectin-7 in patients with metastatic melanoma. "
06/01/2010 - "A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma."
12/01/2006 - "Phase 2 trial of Allovectin-7 in advanced metastatic melanoma."
01/01/2011 - "Immunologic therapy targeting metastatic melanoma: allovectin-7."
06/01/2008 - "Allovectin-7 therapy in metastatic melanoma."
|2.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
07/01/2001 - "To investigate the safety and efficacy of alloantigen plasmid DNA therapy in patients with advanced head and neck squamous cell carcinoma using Allovectin-7 (Vical Inc, San Diego, Calif), a DNA/lipid complex designed to express the class I major histocompatibility complex antigen HLA-B7. "
06/01/2008 - "Allovectin-7 therapy is a form of active immunotherapy that aims at immunization of the host with substances designed to elicit an immune reaction that will eliminate or slow down the growth and spread of the cancer. "
05/01/1995 - "Purified VCL-1005 is formulated with a cationic lipid and injected directly into established tumors of HLA-B7-negative patients with advanced cancers to heighten the patient's immune response against the cancer. "
01/01/2011 - "Allovectin-7 allows the immune system to recognize metastatic melanoma lesions as foreign by incorporating a MHC class I complex into the tumor through direct injection. "
02/01/2002 - "Current evaluation of the drug includes higher Allovectin-7 doses and injection of multiple tumors in metastatic melanoma patients. "
|4.||Head and Neck Neoplasms (Head and Neck Cancer)
02/01/2002 - "Allovectin-7 is being developed as an immunotherapy approach for a variety of malignancies, with special focus on melanoma, and head and neck cancer. "
07/01/2001 - "Intratumoral plasmid DNA immunotherapy for head and neck cancer with Allovectin-7 is safe, and further investigations are planned in patients with less advanced disease, where it could potentially improve patient survival and reduce the need for radical high-morbidity treatments."
|5.||Kidney Neoplasms (Kidney Cancer)
10/01/1999 - "Fifteen patients with histologically confirmed, HLA-B7-negative metastatic renal cancer received intratumoral injection of Allovectin-7 on an escalating dose schedule. "
10/01/1999 - "We investigated the safety and ability to bestow gene expression via intratumoral transfer of escalating amounts of lipid-formulated plasmid DNA encoding for the MHC HLA-B7 gene product Allovectin-7 into metastatic renal cancer lesions. "
|1.||HLA-B7 Antigen (HLA B7 Antigen)
|2.||A-Form DNA (A-DNA)
|5.||DNA (Deoxyribonucleic Acid)
|6.||Interleukin-12 (IL 12)